Connect with us on WeChat

Customer Service

Official Account

Find our office

Level 19, 357 Collins Street, Melbourne, Australia 

Follow us on Linkedin

LinkedIn-Logo-R.png
email-icon.png

(+61) 3 9629 6131

1207314009389168677emergency telephone b

©Copyright 2019 Eureka Technology Innovation & Investment Pty Ltd.

INNOVATION & ENTREPRENEURSHIP TRIP TO CHINA

 December 2018, Zhejiang Province of China

Invited by the hosts of the 10th Zhejiang Tour of Overseas Talents, the 2nd Innovation & Entrepreneurship Trip to China in 2018 was held in Zhejiang Province of China between 17th December and 21st December. The 10th Zhejiang Tour of Overseas Talents is hosted by Science Technology Department of Zhejiang Province China and Yangtze Delta Region Institute of Tsinghua University, and supported by Zhejiang Provincial Government and Tsinghua University. The event provided an outstanding platform and diversified resources for the development and growth of overseas start-up teams.

More than 130 representatives from over 20 countries gathered in Zhejiang Province with their technology innovation and entrepreneurship programs. They visited six cities and learned deeply the innovation and entrepreneurship policies, business environment, culture and market needs in Zhejiang. More than 30% of the representatives intended to mutually collaborate with local enterprises and technology parks.

As the official partner of the event, Eureka Technology Innovation & Investment (EurekaTechIn) proactively supported the hosts in carrying out various activities. EurekaTechIn recommended and brought five innovative and entrepreneurial programs in all to attend the event. They are:

 1. ScoliPro®- a novel diagnostic and prognostic test for Adolescent Idiopathic Scoliosis

 2. EmbedIT: Nano Quantum Dots Embedded Confidence for IP Protection

 3. Artificial Intelligence-based Colorectal Cancer Screening Platform

 4. Intelligent Finance Management Platform under the Big Data

 5. Ternary Lithium-ion polymer batteries of New Energy Cars

It was the first time for many participants to visit China. The participants made pitches, visited local innovation precincts and parks and enterprises in Zhejiang Province, and connected with the governments, investors and other industry practitioners. EpiDesease-ScoliPro® was highly praised by the event organizers, the Government of Zhejiang and investors. It will be land in Zhejiang Province soon with the help of EurekaTechIn and the Government.

WALKING OVER THE GENES

ABOUT EpiDisease-ScoliPro®

EpiDisease is a Spanish biotech company developing and commercializing a pipeline of patented epigenetic products for In vitro diagnostics of human diseases. Our most advanced product is ScoliPro® for the accurate diagnostic and prognostic of adolescent idiopathic scoliosis (AIS).

 

AIS is a tridimensional deformity of the spine accounting for more than 36 million patients around the world (2 million patients in Europe, 1.2 millions in USA and 7 million in China). AIS produces back pain, affects self-esteem and respiratory problems in adolescents. Furthermore, in severe cases it requires costly and risky spine surgery to correct the deformation. The current diagnosis is based on X-rays, but this method does no predict disease progression, so patients should be monitored every six months using X-rays radiographs. However, the continuous exposition to X-rays during disease progression monitoring has demonstrated to increase the risk of cancer in patients. Therefore, clinicians need a new In vitro diagnostic tool to predict scoliosis progression, improve disease management and avoid future deleterious effects produced by X-rays. EpiDisease has developed ScoliPro®, a molecular test based on the detection of circulating microRNAs in blood samples that offers an index that correlates with the severity and risk progression of AIS (Sensitivity 92% and Specificity 73%). With ScoliPro® and associated algorithms we aim to change the current paradigm of disease management and improve personalized treatments for AIS patients. We have estimated that using our technology the direct associated health cost of AIS will be reduced up to 55%.

Want to collaborate with or investment in EpiDisease or ScoliPro®? Please feel free to contact us.